Lineage Cell Therapeutics Inc. — Director's Dealing 2012

Feb 15, 2012

SEC Form 5 — Annual Statement of Changes in Beneficial Ownership

Issuer: BIOTIME INC (BTX)
CIK: 0000876343
Period of Report: 2011-12-31

Reporting Person: TEW WILLIAM P PHD (Chief Commercial Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2011-10-04	Options to Purchase Common Shares	$4.17	A	3850	Acquired	2018-10-02	Common Shares (3850)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Shares, no par value	47125	Direct

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Warrants to Purchase Common Shares	$10.00	2014-05-02	Common Shares (29247)	29247	Direct
Options to Purchase Common Shares	$7.47	2018-03-20	Common Shares (25000)	25000	Direct

Footnotes

F1: Does not include shares that may be acquired upon the exercise of certain stock options, and shares that may be acquired upon the exercise of certain warrants.

F2: 1/48th of the number of options will vest and become exercisable at the end of each full month of employment after March 21, 2011.

F3: 1/48th of the number of options will vest and become exercisable at the end of each full month of employment after October 4, 2011.